LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
Podcasts & Webcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
BioCentury-BayHelix China Healthcare Summit
East-West Healthcare Reception
BioCentury-BayHelix East-West Summit
Bio€quity Europe
BioCentury Grand Rounds Inquiry
The BioCentury Show
Webinars - Upcoming & On-Demand
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a product name.
REQUEST A FREE TRIAL
Product
Deals
Articles
BioCentury
|
Jun 12, 2021
Finance
Right or wrong, the aducanumab decision could turbo-boost investor interest in neurodegeneration
If accelerated approval based on surrogate endpoints becomes a reality, risk takes on a new profile
Read More
BioCentury
|
Apr 29, 2020
Regulation
Zejula’s label expansion reaches an untapped ovarian cancer population
Read More
BioCentury
|
Jul 16, 2019
Clinical News
July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH
Read More
BioCentury
|
Dec 7, 2018
Company News
GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout
Read More
BioCentury
|
Dec 4, 2018
Company News
GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition
Read More
BioCentury
|
Sep 22, 2017
Company News
Management tracks: Unity, Shield, Tusk
Read More
BioCentury
|
Aug 11, 2017
Strategy
The flip-side of immunotherapy
How immuno-oncology targets are spawning new therapies for inflammation
Read More
BioCentury
|
Jun 9, 2017
Clinical News
Prima reports response data from Phase IIb of IMP321 in breast cancer
Read More
BioCentury
|
May 25, 2017
Clinical News
Aprea starts Phase Ib/II of APR-246 for MDS
Read More
BioCentury
|
Apr 27, 2017
Clinical News
IMP321: Ph I TACTI-mel ongoing
Read More
Items per page:
10
1 - 10 of 106